Contact | Print version | PDF version | Send article | RSS feed

Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Quest Diagnostics

27 Feb 2009 - Epigenomics AG announced that it has entered into a non-exclusive licensing agreement for its proprietary biomarker mGSTP1 with U.S.-based Quest Diagnostics Incorporated. Under the agreement, Quest Diagnostics has obtained rights to uses of the GSTP1 DNA methylation biomarker (mGSTP1) to establish and commercialize a molecular-based laboratory-developed test that can help pathologists better diagnose prostate cancer based on testing of a patient's tissue specimen. Financial terms were not disclosed.
 
"We are pleased that Quest Diagnostics is expanding its menu of DNA methylation tests using our technologies and biomarkers. Quest Diagnostics has a strong record of innovation in diagnostics, including development of other DNA methylation diagnostic tests. They also share our goal to develop technologies that will help physicians achieve improved health outcomes for their patients through better diagnosis of prostate cancer and early detection of colorectal cancer", said Geert Nygaard, Chief Executive Officer of Epigenomics.